CHENGDU, CHINA, September 15, 2017 – The 2017 Qiming Venture Partners CEO Summit successfully took place in Chengdu, China. Dr. Jay Mei, CEO and founder of Antengene Corporation, was invited to the summit as a guest speaker for “Future of Innovative Medication Research and Development in China” discussion panel and addressed a speech on how China can leverage oversea clinical development pipeline and accelerate domestic innovative medication research, development and commercialization.
Antengene Corporation is a clinical-stage biopharmaceutical company that focuses on introducing cutting-edge treatments, from mid-to-late stage development pipeline to mature brands, to China and other Asian markets. Antengene’s team consists of industry experts with clinical development and regulatory expertise as well as local market knowledge globally, and especially in Asia Pacific. Driven by a larger purpose, Antengene aims at growing into a market leader in the development of innovative therapies to address unmet medical needs globally in the long term.